Tag Archive for: financing

The Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford have entered into a strategic partnership to accelerate the development of globally accessible vaccines against endemic outbreaks.

Mysthera Therapeutics AG has launched in Basel with $3.5m in seed funding from founding investor Forty51 Ventures. The capital will be used to advance its preclinical portfolio in a variety of autoimmune indications. The focus is on pan-PIM kinase inhibitors that uniquely modulate multilineage immune cell functions.

Women’s health specialist Mithra Pharmaceuticals SA has entered into a definitive agreement to raise €20m in gross proceeds via a private placement of 10 million new ordinary shares with Armistice Capital.

French vaccine maker Valneva SE will double the amount of a US$100m debt financing granted by Deerfield Management Company and OrbiMed.

Swiss Spexis AG  has announced a US$2.5m capital commitment to fund a two-part pivotal Phase III study to get market approval for its inhaled cystic fibrosis antibiotic colistimethate sodium.

British NK cell therapy specialist NK:IO Ltd has added a £1.2m seed investment led by Cancer Research Horizons, bringing total seed funding to £5.1m.

In an oversubscribed capital increase, Carbios SAS has raised €141m, the largest on Euronext growth since 2015.

Paris-based gene therapy vector specialist EG 427 SAS has closed a Series A financing at €18m raising additional €5m in the final closing.

Mallia Therapeutics GmbH has raised seed money to accelerate preclinical research and start Phase I testing of a baldness cure with unique MOA named soluble CD83.

Exeliom Biosciences, a French company focused on the microbiome-immunomodulation axis to develop next-generation immunotherapies, has announced the closing of its €24m (US$26m) Series A financing to advance the clinical development of its therapeutic pipeline, including several clinical trials of EXL01, a novel bacterial immunotherapy with applications in cancer and infectious diseases.